Chemomab Therapeutics (CMMB) EBIAT (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of EBIAT data on file, last reported at $1.9 million in Q4 2025.

• For the quarter ending Q4 2025, EBIAT fell 36.79% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $9.0 million (down 35.5% YoY), and the FY2025 full-year result was -$9.0 million, up 35.5% from the prior year.
• EBIAT for Q4 2025 stood at $1.9 million, up from $1.7 million in the prior quarter.
• Across five years, EBIAT topped out at $8.8 million in Q1 2023 and bottomed at -$45.0 million in Q4 2023.
• The 5-year median for EBIAT is $2.5 million (2024), against an average of -$643250.0.
• The widest annual swing landed in 2022, when EBIAT soared 372.24%; it then tumbled 444.31% in 2023.
• A 5-year view of EBIAT shows it stood at -$5.0 million in 2021, then tumbled by 64.26% to -$8.3 million in 2022, then sank by 444.31% to -$45.0 million in 2023, then surged by 106.58% to $3.0 million in 2024, then tumbled by 36.79% to $1.9 million in 2025.
• The last three EBIAT figures came in at $1.9 million (Q4 2025), $1.7 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.

Peer Comparison